Open help menu
In Person

Medication-Assisted Treatment (MAT) for Adolescent Populations

|

Information

Date & Time

Location

  • 24640 Southpoint Dr
    #140
    Chantilly, Virginia 20152

Description

Medication-Assisted Treatment (MAT) will be examined for an interdisciplinary approach to substance use treatment for adolescents. This course will provide a review for non-prescribing professionals on usage of MAT and the effectiveness, criteria limitations and evidence-based guidance for prescribers within a multidisciplinary SUD team. The lack of American Society of Addiction Medicine (ASAM)-approved medications indicated for adolescents will be discussed to identify systemic barriers and inform interprofessional advocacy, care coordination strategies, and areas of research still needed for using MAT in adolescent SUD treatment

Learning Objectives

Participants will be able to:

  • Define at least three benefits of using MAT with the adolescent population.

  • Identify at least three MAT options approved by ASAM for 16- to 18-year-old patients.

  • Describe three specific criteria required to consider Suboxone treatment for adolescent populations.

  • Explain at least two current research needs required to increase MAT options for adolescent care.

Educational Goal

The educational goal of this workshop is to increase participants' knowledge and clinical guidance to effectively support adolescents receiving Medication-Assisted Treatment.

Target Audience

  • Addiction Professional
  • Counselor
  • Marriage & Family Therapist
  • Nurse
  • Physician
  • Psychologist
  • Social Worker

Presenters

Pamela M. Somervell, MD, ABFM, ABPM: Board Certified in Addiction Medicine. Dr. Somervell graduated from Saint Louis University School of Medicine in 2006. She subsequently completed a Family Medicine residency at Memorial Hospital in South Bend, Indiana. Following residency, she worked as a primary care physician at a Federally Qualified Health Center in rural Southwest Virginia. She became very concerned about the prevalence of substance use disorders in her patient population. Dr. Somervell began providing buprenorphine treatment to her primary care patients with opioid use disorders in 2014 (via the DEA-X waiver program). She became medical director of a methadone clinic (OTP facility) in 2017, and she became Board Certified in Addiction Medicine later that same year. She has treated patients with addiction in a variety of outpatient settings (private clinic, FQHC clinic, Community Service Board, and OTP facility). For the past few years, she has spent most of her time supervising inpatient residential addiction treatment. She is currently the Medical Director for three inpatient substance abuse treatment facilities (two for adults and one for adolescents).

Financially Sponsored By

  • Acadia Healthcare Treatment Placement Specialists® (TPS)